"There is a window of opportunity early in the disease course where the benefits of KISUNLA are significant. We need to do everything possible to diagnose and treat patients at this early stage of the disease," said Tori Brown, the General Manager of Eli Lilly Australia and New Zealand. …
Study reveals growing benefit of Lilly therapy for early symptomatic Alzheimer’s disease
August 1, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News